143 related articles for article (PubMed ID: 6540761)
1. Identification of synergistic combinations of spirogermanium with 5-fluorouracil or cisplatin using a range of human tumour cell lines in vitro.
Hill BT; Bellamy AS; Metcalfe S; Hepburn PJ; Masters JR; Whelan RD
Invest New Drugs; 1984; 2(1):29-33. PubMed ID: 6540761
[TBL] [Abstract][Full Text] [Related]
2. Spirogermanium--a novel antitumour agent expressing a lack of cross-resistance in vitro with a range of 'standard' antitumour drugs.
Hill BT; Whelan RD
Invest New Drugs; 1986; 4(4):359-65. PubMed ID: 3583643
[TBL] [Abstract][Full Text] [Related]
3. Combination of cisplatin-procaine complex DPR with anticancer drugs increases cytotoxicity against ovarian cancer cell lines.
Viale M; Pastrone I; Pellecchia C; Vannozzi MO; Cafaggi S; Esposito M
Anticancer Drugs; 1998 Jun; 9(5):457-63. PubMed ID: 9660544
[TBL] [Abstract][Full Text] [Related]
4. Cytotoxic effects and biological activity of 2-aza-8-germanspiro[4,5]-decane-2-propanamine-8,8-diethyl-N,N-dimethyl dichloride (NSC 192965; spirogermanium) in vitro.
Hill BT; Whatley SA; Bellamy AS; Jenkins LY; Whelan RD
Cancer Res; 1982 Jul; 42(7):2852-6. PubMed ID: 7200828
[TBL] [Abstract][Full Text] [Related]
5. Enhanced antitumor activity of irofulven in combination with 5-fluorouracil and cisplatin in human colon and ovarian carcinoma cells.
Poindessous V; Koeppel F; Raymond E; Cvitkovic E; Waters SJ; Larsen AK
Int J Oncol; 2003 Nov; 23(5):1347-55. PubMed ID: 14532976
[TBL] [Abstract][Full Text] [Related]
6. The synergistic and antagonistic effects of cytotoxic and biological agents on the in vitro antitumour effects of suramin.
Lopez Lopez R; van Rijswijk RE; Wagstaff J; Pinedo HM; Peters GJ
Eur J Cancer; 1994; 30A(10):1545-9. PubMed ID: 7833116
[TBL] [Abstract][Full Text] [Related]
7. [Choice of second-line chemotherapy for advanced breast cancer based on the chemosensitivity assay by in vitro colony assay].
Inoue K; Mukaiyama T; Yamazaki H; Horikoshi N; Ogawa M; Kobayashi T; Aiba K; Kuraishi Y
Gan To Kagaku Ryoho; 1986 Feb; 13(2):356-61. PubMed ID: 3080968
[TBL] [Abstract][Full Text] [Related]
8. Tumor necrosis factor and cytotoxic agents. Effect on squamous carcinoma lines.
Gapany M; Dawson DE; Schriever C; Burgess R; Gipple JR; Riggs CE
Arch Otolaryngol Head Neck Surg; 1990 Apr; 116(4):436-9. PubMed ID: 2317326
[TBL] [Abstract][Full Text] [Related]
9. Spirogermanium: a new investigational drug of novel structure and lack of bone marrow toxicity.
Slavik M; Blanc O; Davis J
Invest New Drugs; 1983; 1(3):225-34. PubMed ID: 6678870
[TBL] [Abstract][Full Text] [Related]
10. Cytotoxicity of cisplatin and carboplatin used alone and in combination with the other anticancer drugs in the mouse embryo C3H10T1/2 cell line.
Hussain SS; Amer MH; Hannan MA
Chemotherapy; 1988; 34(6):504-11. PubMed ID: 2468457
[TBL] [Abstract][Full Text] [Related]
11. Phase I evaluation of spirogermanium and 5-fluorouracil in colorectal carcinoma.
Williamson SK; Slavik M
Invest New Drugs; 1991 Feb; 9(1):49-52. PubMed ID: 2026484
[TBL] [Abstract][Full Text] [Related]
12. In-vitro effect of a combination of 5-fluorouracil (5-FU) and cisplatin (CDDP) on human gastric cancer cell lines: timing of cisplatin treatment.
Cho H; Imada T; Oshima T; Shiozawa M; Rino Y; Takanashi Y
Gastric Cancer; 2002; 5(1):43-6. PubMed ID: 12021859
[TBL] [Abstract][Full Text] [Related]
13. A study of various strategies to enhance the cytotoxic activity of 5-fluorouracil/leucovorin in human colorectal cancer cell lines.
Scheithauer W; Temsch EM
Anticancer Res; 1989; 9(6):1793-8. PubMed ID: 2627128
[TBL] [Abstract][Full Text] [Related]
14. Synergy is documented in vitro with low-dose recombinant tumor necrosis factor, cisplatin, and doxorubicin in ovarian cancer cells.
Bonavida B; Tsuchitani T; Zighelboim J; Berek JS
Gynecol Oncol; 1990 Sep; 38(3):333-9. PubMed ID: 2227544
[TBL] [Abstract][Full Text] [Related]
15. Cytotoxic synergy between flavopiridol (NSC 649890, L86-8275) and various antineoplastic agents: the importance of sequence of administration.
Bible KC; Kaufmann SH
Cancer Res; 1997 Aug; 57(16):3375-80. PubMed ID: 9269999
[TBL] [Abstract][Full Text] [Related]
16. Anti-proliferative activity and mechanism of action of titanocene dichloride.
Christodoulou CV; Eliopoulos AG; Young LS; Hodgkins L; Ferry DR; Kerr DJ
Br J Cancer; 1998 Jun; 77(12):2088-97. PubMed ID: 9649119
[TBL] [Abstract][Full Text] [Related]
17. [In vitro chemosensitivity test for testicular cancer using a human tumor stem cell assay].
Yamamoto N; Matsuyama H; Shinohara Y; Shimizu K; Sakatoku J
Nihon Gan Chiryo Gakkai Shi; 1985 Dec; 20(10):2229-35. PubMed ID: 2420907
[No Abstract] [Full Text] [Related]
18. Cytotoxicity of dimethyl sulfoxide and antineoplastic combinations against human tumors.
Pommier RF; Woltering EA; Milo G; Fletcher WS
Am J Surg; 1988 May; 155(5):672-6. PubMed ID: 3369622
[TBL] [Abstract][Full Text] [Related]
19. The synergistic cytotoxicity of cisplatin and taxol in killing oral squamous cell carcinoma.
Huang GC; Liu SY; Lin MH; Kuo YY; Liu YC
Jpn J Clin Oncol; 2004 Sep; 34(9):499-504. PubMed ID: 15466821
[TBL] [Abstract][Full Text] [Related]
20. Synergistic cytotoxicity between dimethyl sulfoxide and antineoplastic agents against ovarian cancer in vitro.
Pommier RF; Woltering EA; Milo G; Fletcher WS
Am J Obstet Gynecol; 1988 Oct; 159(4):848-52. PubMed ID: 3177534
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
